The Market Reports

Index

1 Gene Therapy Viral Vector and Plasmid DNA Market Overview
1.1 Product Overview and Scope of Gene Therapy Viral Vector and Plasmid DNA
1.2 Gene Therapy Viral Vector and Plasmid DNA Segment by Type
1.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Value Comparison by Type (2023-2029)
1.2.2 Viral Vectors
1.2.3 Plasmid DNA
1.3 Gene Therapy Viral Vector and Plasmid DNA Segment by Application
1.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Value by Application: (2023-2029)
1.3.2 Cell and Gene Therapy
1.3.3 Vaccine Development
1.3.4 Research
1.4 Global Gene Therapy Viral Vector and Plasmid DNA Market Size Estimates and Forecasts
1.4.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue 2018-2029
1.4.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales 2018-2029
1.4.3 Global Gene Therapy Viral Vector and Plasmid DNA Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Gene Therapy Viral Vector and Plasmid DNA Market Competition by Manufacturers
2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Manufacturers (2018-2023)
2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Manufacturers (2018-2023)
2.4 Global Gene Therapy Viral Vector and Plasmid DNA Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Gene Therapy Viral Vector and Plasmid DNA, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gene Therapy Viral Vector and Plasmid DNA, Product Type & Application
2.7 Gene Therapy Viral Vector and Plasmid DNA Market Competitive Situation and Trends
2.7.1 Gene Therapy Viral Vector and Plasmid DNA Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gene Therapy Viral Vector and Plasmid DNA Players Market Share by Revenue
2.7.3 Global Gene Therapy Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gene Therapy Viral Vector and Plasmid DNA Retrospective Market Scenario by Region
3.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Global Gene Therapy Viral Vector and Plasmid DNA Sales by Region: 2018-2029
3.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Region: 2018-2023
3.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Region: 2024-2029
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Region: 2018-2029
3.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Region: 2018-2023
3.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Region: 2024-2029
3.4 North America Gene Therapy Viral Vector and Plasmid DNA Market Facts & Figures by Country
3.4.1 North America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2029)
3.4.3 North America Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gene Therapy Viral Vector and Plasmid DNA Market Facts & Figures by Country
3.5.1 Europe Gene Therapy Viral Vector and Plasmid DNA Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2029)
3.5.3 Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Market Facts & Figures by Country
3.6.1 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2029)
3.6.3 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gene Therapy Viral Vector and Plasmid DNA Market Facts & Figures by Country
3.7.1 Latin America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2029)
3.7.3 Latin America Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Market Facts & Figures by Country
3.8.1 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2029)
3.8.3 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2029)
4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023)
4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2024-2029)
4.1.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2029)
4.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2018-2029)
4.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2018-2023)
4.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2024-2029)
4.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2018-2029)
4.3 Global Gene Therapy Viral Vector and Plasmid DNA Price by Type (2018-2029)
5 Segment by Application
5.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2029)
5.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023)
5.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2024-2029)
5.1.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2029)
5.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2018-2029)
5.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2018-2023)
5.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2024-2029)
5.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application (2018-2029)
5.3 Global Gene Therapy Viral Vector and Plasmid DNA Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Lonza
6.1.1 Lonza Corporation Information
6.1.2 Lonza Description and Business Overview
6.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.1.5 Lonza Recent Developments/Updates
6.2 Merck KGaA
6.2.1 Merck KGaA Corporation Information
6.2.2 Merck KGaA Description and Business Overview
6.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.2.5 Merck KGaA Recent Developments/Updates
6.3 Thermo Fisher Scientific
6.3.1 Thermo Fisher Scientific Corporation Information
6.3.2 Thermo Fisher Scientific Description and Business Overview
6.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.3.5 Thermo Fisher Scientific Recent Developments/Updates
6.4 Charles River Laboratories
6.4.1 Charles River Laboratories Corporation Information
6.4.2 Charles River Laboratories Description and Business Overview
6.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.4.5 Charles River Laboratories Recent Developments/Updates
6.5 Catalent
6.5.1 Catalent Corporation Information
6.5.2 Catalent Description and Business Overview
6.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.5.5 Catalent Recent Developments/Updates
6.6 WuXi AppTec
6.6.1 WuXi AppTec Corporation Information
6.6.2 WuXi AppTec Description and Business Overview
6.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.6.4 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.6.5 WuXi AppTec Recent Developments/Updates
6.7 FUJIFILM
6.6.1 FUJIFILM Corporation Information
6.6.2 FUJIFILM Description and Business Overview
6.6.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.4.4 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.7.5 FUJIFILM Recent Developments/Updates
6.8 GenScript Biotech
6.8.1 GenScript Biotech Corporation Information
6.8.2 GenScript Biotech Description and Business Overview
6.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.8.5 GenScript Biotech Recent Developments/Updates
6.9 Takara Bio
6.9.1 Takara Bio Corporation Information
6.9.2 Takara Bio Description and Business Overview
6.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.9.5 Takara Bio Recent Developments/Updates
6.10 Oxford Biomedica
6.10.1 Oxford Biomedica Corporation Information
6.10.2 Oxford Biomedica Description and Business Overview
6.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.10.5 Oxford Biomedica Recent Developments/Updates
6.11 Novartis
6.11.1 Novartis Corporation Information
6.11.2 Novartis Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.11.5 Novartis Recent Developments/Updates
6.12 Precision Biosciences
6.12.1 Precision Biosciences Corporation Information
6.12.2 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.12.5 Precision Biosciences Recent Developments/Updates
6.13 Bluebird Bio
6.13.1 Bluebird Bio Corporation Information
6.13.2 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.13.5 Bluebird Bio Recent Developments/Updates
6.14 Sartorius AG
6.14.1 Sartorius AG Corporation Information
6.14.2 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.14.5 Sartorius AG Recent Developments/Updates
6.15 Danaher
6.15.1 Danaher Corporation Information
6.15.2 Danaher Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.15.5 Danaher Recent Developments/Updates
6.16 SIRON Biotech
6.16.1 SIRON Biotech Corporation Information
6.16.2 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.16.4 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.16.5 SIRON Biotech Recent Developments/Updates
6.17 VGXI
6.17.1 VGXI Corporation Information
6.17.2 VGXI Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.17.4 VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.17.5 VGXI Recent Developments/Updates
6.18 Waisman Biomanufacturing
6.18.1 Waisman Biomanufacturing Corporation Information
6.18.2 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.18.5 Waisman Biomanufacturing Recent Developments/Updates
6.19 Kaneka Eurogentec
6.19.1 Kaneka Eurogentec Corporation Information
6.19.2 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.19.5 Kaneka Eurogentec Recent Developments/Updates
6.20 PlasmidFactory
6.20.1 PlasmidFactory Corporation Information
6.20.2 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.20.4 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.20.5 PlasmidFactory Recent Developments/Updates
6.21 ATUM
6.21.1 ATUM Corporation Information
6.21.2 ATUM Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.21.4 ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.21.5 ATUM Recent Developments/Updates
6.22 Addgene
6.22.1 Addgene Corporation Information
6.22.2 Addgene Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.22.5 Addgene Recent Developments/Updates
6.23 Cell and Gene Therapy Catapult
6.23.1 Cell and Gene Therapy Catapult Corporation Information
6.23.2 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.23.5 Cell and Gene Therapy Catapult Recent Developments/Updates
6.24 Batavia biosciences
6.24.1 Batavia biosciences Corporation Information
6.24.2 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.24.5 Batavia biosciences Recent Developments/Updates
6.25 Altogen Biosystems
6.25.1 Altogen Biosystems Corporation Information
6.25.2 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Description and Business Overview
6.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolio
6.25.5 Altogen Biosystems Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gene Therapy Viral Vector and Plasmid DNA Industry Chain Analysis
7.2 Gene Therapy Viral Vector and Plasmid DNA Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gene Therapy Viral Vector and Plasmid DNA Production Mode & Process
7.4 Gene Therapy Viral Vector and Plasmid DNA Sales and Marketing
7.4.1 Gene Therapy Viral Vector and Plasmid DNA Sales Channels
7.4.2 Gene Therapy Viral Vector and Plasmid DNA Distributors
7.5 Gene Therapy Viral Vector and Plasmid DNA Customers
8 Gene Therapy Viral Vector and Plasmid DNA Market Dynamics
8.1 Gene Therapy Viral Vector and Plasmid DNA Industry Trends
8.2 Gene Therapy Viral Vector and Plasmid DNA Market Drivers
8.3 Gene Therapy Viral Vector and Plasmid DNA Market Challenges
8.4 Gene Therapy Viral Vector and Plasmid DNA Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer